IR Presentation
This presentation is the property of its rightful owner.
Sponsored Links
1 / 19

for Growth PowerPoint PPT Presentation


  • 109 Views
  • Uploaded on
  • Presentation posted in: General

IR Presentation. for Growth. NEW Run for Growth. This IR Presentation contains forward-looking statements that involve risks and uncertainties.

Download Presentation

for Growth

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -

Presentation Transcript


For growth

IR Presentation

for Growth


For growth

NEW Run for Growth

This IR Presentation contains forward-looking statements that involve risks and uncertainties.

The actual results may differ from those we project and may be affected by business environment, government regulation and legislation, financial market movement, etc.


For growth

  • LG Life Sciences…

  • Products Line-up

  • R&D Activities

  • Core Values


For growth

History & Growth Pathway

Global

Company

Gearing-up

Building-up

2011

NCE Research

Bio Research

2006

2002

1994

1983

  • Pharmaceutical business initiated

  • NCE Research

  • Stabilizing operation

  • Critical mass

  • Global market

    presence

  • World-class

    performance

Target

  • Bio research

  • Acquired AN-JIN Pharm corp.

  • Strategic alliance

  • Euvax B, Eutropin

  • Zanidip, Eutropin

  • Out-licensing

  • R&D productivity

  • Sales efficiency

  • Global products

  • Innovative R&D

Growth

Driver

  • First launch of bio-pharmaceuticals in Korea

    (Interferon, hGH)

  • Factive, out-licensed to SB

  • Strategic alliance with BioPartners

  • Factive, approved from US FDA

  • Marketing alliance

    with Novartis(Korea)

  • Caspase inhibitor, out-licensed to Gilead

Milestone


For growth

Business Activities - Domestic

Seoul

  •  Head Office: Seoul

  • R&D Center: Daejeon

  • Plants : Iksan (Pharmaceuticals, rBST)

    Onsan (API, Agrochemicals)

  • Sales Offices : 11 major cities

  • Total Personnel : 1,100 (R&D 30%, Sales 30%

    Manufacturing 30%)

Daejeon

Onsan

Iksan


For growth

Business Activities - Overseas

  • LGLSI(India) Personnel : 130

  • China Branch Personnel : 3

  • Global Alliances

  • Total 25 Products

  • Euvax B

  • Valtropin

  • Factive

  • Factive

  • Insecticide

  • Infertility

  • Euvax B

  • Eutropin

  • Espogen

  • Factive

North

America

(11%)

EU

(7%)

  • Euvax B

  • Factive

  • Insecticide

  • Boostin

  • Espogen

  • Others

Middle

East

(11%)

Africa

(4%)

  • Boostin

  • Euvax B

  • Eutropin

  • Espogen

  • Factive

  • Insecticide

  • Euvax B

  • Boostin

  • Espogen

  • Infertility

South

America

(29%)

Asia

(36%)

2007 Overseas Sales

($80M, 36%)


For growth

Business Results

Annual Results (Bil KRW)

Quarterly Results(Bil KRW)

Sales(royalties)

Operating Income

Sales(royalties)

Operating Income

(24.1)

(20.6)

(3.4)

(20.2)

(8.5)

(1.2)

(1.3)

(20.1)

(2.0)

(0.1)


For growth

  • LG Life Sciences…

  • Products Line-up

  • R&D Activities

  • Core Values


For growth

Euvax B

Zanidip

Eutropin

Others

Factive

Hyruan

Plus

20 15 10 5 1

In-house

L/I

’02 ’04 ’06 ‘08 ’10

Products Line-up

Newly Defined

Therapeutic Areas

Market & Customer

(Mega-trend)

Ex-product Portfolio

  • Undefined TA (therapeutic area)

  • Product-centered approach

  • In-house R&D interest

Chronic

Disease

Slide

10

Aging Society

Well-being

Slide

11

Income Level

Improvement

New Approach

Number of products

  • Clearly defined TA(therapeutic area)

  • Product line-up based on newly defined TA

  • Market & Customer friendly

Increased Need

for Preventive

Healthcare

Preventive

Healthcare

Slide

12

Others

Co-Marketing


For growth

Chronic Disease

  • CCB : Calcium Channel Blocker

  • ARB : Angiotensin Ⅱ Receptor Blocker


For growth

Well-being

  • GHD : Growth Hormone Deficiency

  • IVF-M : HMG (human menopausal gonadotropin)

  • IVF-C : HCG (human chorionic gonadotropin)

  • ART : Assistant Reproductive Technology


For growth

Preventive Healthcare

Vaccines

Diagnostics

  • ELISA : Enzyme-linked Immunosorbent Assay, - POCT : Point-of-care Testing

  • real time PCR : Polymerase Chain Reaction


For growth

API Business

FactiveTM

  • Quinolone antibioticfor respiratory tract infection

  • 1st US FDA-approved drug in Korea

  • Indication

    - 5-dayCAP, AECB, ABS

    - Excellent efficacy, better patient compliance

  • Globalization

    - US : Launched in Sep. 2004 (Oscient)

    - Mexico (Pfizer), Canada (Abbott), EU (Menarini) : Sub-licensed by Oscient

    - Russia, South Africa, China, Brazil, Turkey, Middle East, etc. : Launching

CMO Business

(Bil KRW)

  • CAP : Community Acquired Pneumonia, - AECB : Acute Exacerbations of Chronic Bronchitis

  • ABS : Acute Bacterial Sinusitis, - CMO : Contract Manufacturing Organization


For growth

  • LG Life Sciences…

  • Products Line-up

  • R&D Activities

  • Core Values


For growth

PhaseⅡ/Ⅲ,

Approval

Target

Candidate,

Pre/PhaseⅠ

Alliance /

Outsourcing

Enhancing R&D productivity

Focused R&D (Outside-In)

Risk Management (Open Innovation)

  • Growth

  • Anti-aging

  • Infertility

  • Obesity

  • Value Creation

Competitiv-eness

Well-being

Global Pharma

Market &

Customer

(Mega-trend)

Chronic

Disease

Out-licensing /

Co-development

Preventive

Healthcare

  • Cardiovascular

  • Diabetes

  • Liver disease

  • Degenerative

  • arthritis

Cost

  • Combo-vaccine

  • Diagnostics


For growth

R&D Pipeline – New Chemical Entities

  • HBV : Hepatitis B Virus

  • DPP-IV : Dipeptidyl Peptidase IV

  • ROW : Rest Of The World


For growth

R&D Pipeline – Biologics

  • DTaP : Diphtheria, Tetanus toxoids, acellular(whole cell) Pertussis adsorbed

  • ROW : Rest Of The World


For growth

NEW Run for Growth

  • LG Life Sciences…

  • Products Line-up

  • R&D Activities

  • Core Values


For growth

LG Way

LG’s vision is to become the best in its class

By winning customer’s acclaim

as a leader in the global market

Vision

No.1 LG

“Jeong-Do” Management is LG’s unique

code of conduct that governs our management

activities. The English translation of

“Jeong-Do” is “the right way”.

“Jeong-Do”

Management

Code of Conduct

- LG provides equal

opportunities for its

employees

- LG rewards its employees

based on their capabilities

and performance

- LG serves customers

with integrity

- LG strives to build

competence through

innovation

Respecting Human dignity

Creating value for customers

Managemnet

Principles


  • Login